Skip to content

Use of Adipose-Derived Stem/Stromal Cells in Concussion and Traumatic Brain Injuries

Use of Adipose-Derived Cellular Stromal Vascular Fraction (AD-cSVF) Parenterally in Post-Concussion Injuries and Traumatic Brain Injuries (TBI)

Status
Withdrawn
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02959294
Acronym
C-TBI
Enrollment
0
Registered
2016-11-09
Start date
2018-11-30
Completion date
2024-03-31
Last updated
2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Concussion, Brain, Concussion, Intermediate, Concussion, Mild, Concussion, Severe, Traumatic Encephalopathies, Chronic

Keywords

TBI, mTBI, Concussion, Brain, Loss Consciousness, Traumatic, Headaches

Brief summary

Concussion is the most common type of brain injury throughout life. Study is seeking improvement of long-term residua following adolescent and adult post-traumatic injuries often associated with contact sports and accidental causes. Typically defined as reversible head injury with temporary loss of brain function. Symptoms range from physical, cognitive, pain (headache) and emotional signs consistent with TBI and Post-Traumatic Stress Syndrome. Use of AD-cSVF parenteral delivery to encourage repair of damage and decreased function following concussion, particularly in contact, repetitive sports injuries. Range of damage is measured in Grade I-III according to graduated severity. Unfortunately, less information is available about repetitive concussions and the long-term health issues.

Detailed description

Concussion Syndrome (CS) and TBI are common injuries producing temporary and long-term damage to impact brain function. Symptoms are sometimes transient, sometimes long-term depending on severity and/or repetitive damage. Signs varying from recurrent headaches, mental fog, emotional changes to physical signs of loss of consciousness, amnesia to behavioral change (irritability, loss of concentration ability, etc.), cognitive impairment (slow reaction times, memory loss), and recurring sleep disturbances. Common causes include sports injuries, automobile accidents, falls, blunt trauma to head, and explosive/blast injuries from production of acceleration injuries Treatment often involves monitoring, physical rest, limiting cognitive activities (such as computing, video games, texting, and studying). Most often a single episode usually resolve or improve (particularly in recurring headaches) within 3-4 weeks. It is estimated that \>6/1000 occurrence rate apply. Repetitive injuries seem to make the person more susceptible to additional damage, particularly with injury precedes resolution of an earlier damage. There appears also to make persons to require a lesser impact to produce the same degree of severity. It is becoming more recognized that repeated concussions increase the risks in later life for dementia, Parkinson's and severe depressions. Most serious signs to evaluate are loss of consciousness, seizures, worsening headache, diplopia/pupil changes, loss of recognition, vomiting, focal neurological problems, and change of personality. There is no consensus definition of concussion or TBI. Most concussions are considered in the mild TBI (mTBI) group, and are rarely demonstrate structural brain damage when in the acute to subacute state. Late brain MRI changes are difficult to clearly point to or identify the specific areas of presumed damage. This study is intended to examine safety and efficacy of parenteral introduction of AD-cSVF in cases of CS and TBI, and categorically examine the outcomes according to the elapsed time from original concussive event. No delineation of those having recurrent damage and injuries are made within this study.

Interventions

Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells

Use of Centricyte 1000 Closed System Digestion Autologous AD-tSVF to create AD-cSVF

Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use

Sponsors

Robert W. Alexander, MD, FICS
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Documented history of mTBI or TBI with Correlated MRI or CT * At least 1 month post mTBI and TBI * Able and Willing to participate in CT or MRI pre-study and at 3 year, 5 year interval * Able to provide informed consent to undergo the study * Depression, Cognitive Disability, Attention Disorders, Headaches or other persistent changes which followed a traumatic brain event (TBI) * Impaired social or occupational functioning following mTBI or TBI * History of repetitive events for mTBI and TBI

Exclusion criteria

* Documented history of neuro-degenerative illness, seizures, mental illness, or severe medical conditions preceding mTBI or TBI * Malignances, Bleeding Disorders, Pregnancy or Lactation * Tumors of Central Nervous System (CNS) * Lack of adequate donor tissue volume as determined by the primary investigator at their discretion * Any pre-existing medical condition which, in view of the primary investigator and patient's primary care physician, would prevent participation in study

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with adverse eventsOutcome measures at baseline at 6 monthActivities of Daily Living (ADL)
Cognitive Change in clinical symptoms associated with concussion-TBIOutcome measures at baseline and reviewed 1 year interval for average time 5 yearsMontreal Cognitive Assessment Scale (MCAS)

Secondary

MeasureTime frameDescription
Beck's Depression Inventory (BDI)Annual for 5 yearsMultiple choice self reporting measure of depression
Adult Attention Deficit AssessmentAnnual for 5 yearsConner's Adult Attention Deficit Disorder Rate Scale (CAADDR)
MRI Brain With & MRI Brain With & Without Contrast0, 3 years, 5 yearsMRI Brain to evaluate progressive changes comparing pre-treatment (0), 3 year and 5 year status

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026